The Effect of Low Dose Combined Hormone Therapy (Estradiol And Norethindrone Acetate) on Serum CRP Levels and Life Quality in Natural Menopause Women
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 主要终点
- Blood was drawn for basal CRP from all patients
研究概览
简要总结
This study aims to assess the effect of low dose combined estradiol and norethindrone acetate hormone therapy on serum CRP levels and life quality in natural menopause women. 45 natural menopause women who admitted to Karadeniz Technical University, Faculty of Medicine, Department of Obstetrics and Gynaecology for 1 year and diagnosed as menopause and planned to have hormone therapy for menopausal symptoms involved in this study. The serum CRP levels and vasomotor symptoms scores graded according to Blatt-Kupperman Index and life quality scores according to Menopause-Specific Quality of Life Questionnaire (MENQOL) in Turkish were recorded before and after (3 months later) low dose hormone treatment (1 mg Estradiol and 0.5 mg Norethindrone acetate).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 45 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Accepting consent to participate in the research and signing the form;
- •Postmenopausal women 45-55 years old
- •not having had menstruation for the past 6 months;
- •Hormone results compatible with menopause (FSH> 20 milli-International unit(mIU) / mL, E2 <20 mIU / mL) and presence of vasomotor and/or menopausal symptoms (moderate to severe);
- •no systemic disease (Diabetes, hypertension, hyperlipidemia, ischemic heart disease), or no infectious disease in the past 2 weeks;
- •not taking any hormone therapy or medication for at least 2 months;
- •no contraindications for hormone therapy in routine menopause evaluation;
- •Willingness to take hormone therapy
- •No smoking.
排除标准
- •Any systemic disease (DM, HT, hyperlipidemia, ischemic heart disease) presence
- •Contraindications for hormone therapy
- •Failure to follow-up
- •Inability to complete three months of hormone therapy
- •Stopping hormone therapy due to vaginal bleeding during hormone therapy
结局指标
主要结局
Blood was drawn for basal CRP from all patients
时间窗: 12 months
The patients who were evaluated for the Blatt-Kupperman index and MENQOL questionnaire were given three months of treatment to the patient, which included 1.03 mg , Estradiol hemihydrate and 0.5 mg Norethindrone acetate
次要结局
未报告次要终点
研究者
Suleyman Guven
professor
Karadeniz Technical University